Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Infectious Disease - Page 44

Infectious Disease

Mesa Biotech received  $15.4 million funding from the NIH for accelerated scale-up and deployment
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | NIH

Mesa Biotech received $15.4 million funding from the NIH for accelerated scale-up and deployment

On Jul. 21, 2020, Mesa Biotech announced it had been awarded a contract up to $15.4 million from…

Read More Mesa Biotech received $15.4 million funding from the NIH for accelerated scale-up and deploymentContinue

Thermo Fisher Scientific’s to support development and production of  COVID-19 therapeutics and vaccines
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

Thermo Fisher Scientific’s to support development and production of COVID-19 therapeutics and vaccines

On Jul. 20, 2020, Thermo Fisher Scientific expanded global capacity and capabilities across its leading pharma services network…

Read More Thermo Fisher Scientific’s to support development and production of COVID-19 therapeutics and vaccinesContinue

Valneva confirmed participation in UK Government COVID-19 Vaccine Response Program
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Valneva confirmed participation in UK Government COVID-19 Vaccine Response Program

On Jul. 20, 2020, Valneva confirmed its participation in the UK government COVID-19 vaccine response program. Valneva had…

Read More Valneva confirmed participation in UK Government COVID-19 Vaccine Response ProgramContinue

Dynavax and Mount Sinai announced collaboration to develop a universal influenza vaccine candidate with CpG 1018 adjuvant
Biotechnology | Infectious Disease | Influenza | Vaccine

Dynavax and Mount Sinai announced collaboration to develop a universal influenza vaccine candidate with CpG 1018 adjuvant

On Jul. 16, 2020, Dynavax Technologies and the Icahn School of Medicine at Mount Sinai announced they had…

Read More Dynavax and Mount Sinai announced collaboration to develop a universal influenza vaccine candidate with CpG 1018 adjuvantContinue

Tonix Pharma announced research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Tonix Pharma announced research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics

On Jul. 16, 2020, Tonix Pharmaceuticals announced it had entered into a research collaboration and option agreement with…

Read More Tonix Pharma announced research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeuticsContinue

Tevogen Bio announced steps toward proprietary T Cell therapy for development of bivalent vaccine for COVID-19 and influenza
Biotechnology | COVID-19 | Infectious Disease | Influenza | Vaccine

Tevogen Bio announced steps toward proprietary T Cell therapy for development of bivalent vaccine for COVID-19 and influenza

On Jul. 15, 2020, Tevogen Bio announced its intention to evaluate its proprietary antigen-specific T cell technology as…

Read More Tevogen Bio announced steps toward proprietary T Cell therapy for development of bivalent vaccine for COVID-19 and influenzaContinue

Moderna announced publication in The New England Journal of Medicine of interim results from phase 1 study of its mRNA vaccine against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced publication in The New England Journal of Medicine of interim results from phase 1 study of its mRNA vaccine against COVID-19

On Jul. 14, 2020, Moderna announced the publication of an interim analysis of the open-label Phase 1 study…

Read More Moderna announced publication in The New England Journal of Medicine of interim results from phase 1 study of its mRNA vaccine against COVID-19Continue

Pascal Biosciences discovered a cannabinoid that combats Coronavirus
Biotechnology | COVID-19 | Infectious Disease | Medicine | Therapeutics

Pascal Biosciences discovered a cannabinoid that combats Coronavirus

On Jul. 14, 2020, Pascal Biosciences announced it had discovered certain cannabinoids that block replication of SARS-CoV-2, the…

Read More Pascal Biosciences discovered a cannabinoid that combats CoronavirusContinue

Tonix Pharma entered into research and exclusive license option agreement with Kansas State University to develop vaccine against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Influenza | Vaccine

Tonix Pharma entered into research and exclusive license option agreement with Kansas State University to develop vaccine against COVID-19

On Jul. 13, 2020, Tonix Pharmaceuticals announced a new preclinical research and option agreement with Kansas State University…

Read More Tonix Pharma entered into research and exclusive license option agreement with Kansas State University to develop vaccine against COVID-19Continue

UT Southwestern, Texas Health launched collaborative study to better understand COVID prevalence in DFW
COVID-19 | Infectious Disease | Therapeutics

UT Southwestern, Texas Health launched collaborative study to better understand COVID prevalence in DFW

On Jul. 10, 2020, researchers at UT Southwestern Medical Center and Texas Health Resources announced that they will…

Read More UT Southwestern, Texas Health launched collaborative study to better understand COVID prevalence in DFWContinue

Moderna and ROVI announced collaboration for OUS fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Moderna and ROVI announced collaboration for OUS fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate

On Jul. 9, 2020 Moderna and Laboratorios Farmaceuticos Rovi announced a collaboration for large-scale, commercial fill-finish manufacturing of…

Read More Moderna and ROVI announced collaboration for OUS fill-finish manufacturing of Moderna’s COVID-19 vaccine candidateContinue

From lung scarring to heart damage, COVID-19 may leave lingering marks
Biotechnology | COVID-19 | Infectious Disease | Vaccine

From lung scarring to heart damage, COVID-19 may leave lingering marks

On Jul. 8, 2020, scientists at the UC Berkeley-UCSF Joint Medical Program reported that for some individuals with…

Read More From lung scarring to heart damage, COVID-19 may leave lingering marksContinue

Moderna completed enrollment of phase 2 study of its mRNA vaccine against COVID-19 (mRNA-1273)
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna completed enrollment of phase 2 study of its mRNA vaccine against COVID-19 (mRNA-1273)

On Jul. 8, 2020, Moderna announced that it had completed enrollment for both cohorts of the Phase 2…

Read More Moderna completed enrollment of phase 2 study of its mRNA vaccine against COVID-19 (mRNA-1273)Continue

BD partnered with U.S. Government on $70 million manufacturing infrastructure project for mass vaccination campaigns
Biotechnology | COVID-19 | Infectious Disease | Medical Device | Vaccine

BD partnered with U.S. Government on $70 million manufacturing infrastructure project for mass vaccination campaigns

On Jul. 8, 2020, BD (Becton, Dickinson) announced the formation of a strategic, public-private partnership with the Biomedical…

Read More BD partnered with U.S. Government on $70 million manufacturing infrastructure project for mass vaccination campaignsContinue

First adjuvanted quadrivalent influenza vaccine received EU approval
Biotechnology | Infectious Disease | Influenza | Vaccine

First adjuvanted quadrivalent influenza vaccine received EU approval

On Jul. 8, 2020, the European Commission announced regulatory approval for the first adjuvanted quadrivalent influenza vaccine to…

Read More First adjuvanted quadrivalent influenza vaccine received EU approvalContinue

Fred Hutch joined international COVID-19 vaccine effort
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Fred Hutch joined international COVID-19 vaccine effort

On Jul. 8, 2020, the Fred Hutchinson Cancer Research Center was named the coordinating center for vaccine clinical…

Read More Fred Hutch joined international COVID-19 vaccine effortContinue

Texas A&M, MD Anderson Scientists tested inhaled therapeutic to protect against COVID-19
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics

Texas A&M, MD Anderson Scientists tested inhaled therapeutic to protect against COVID-19

On Jul. 8, 2020, scientists from Texas A&M University, biopharmaceutical company Pulmotect and MD Anderson Cancer Center announced…

Read More Texas A&M, MD Anderson Scientists tested inhaled therapeutic to protect against COVID-19Continue

Novavax announced $1.6 billion funding from Operation Warp Speed
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax announced $1.6 billion funding from Operation Warp Speed

On Jul. 7, 2020, Novavax announced that it had been selected to participate in Operation Warp Speed, a…

Read More Novavax announced $1.6 billion funding from Operation Warp SpeedContinue

Regeneron announced manufacturing and supply agreement for BARDA and U.S. DoD for REGN-COV2 anti-viral antibody cocktail
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Regeneron announced manufacturing and supply agreement for BARDA and U.S. DoD for REGN-COV2 anti-viral antibody cocktail

On Jul. 7, 2020, Regeneron announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and…

Read More Regeneron announced manufacturing and supply agreement for BARDA and U.S. DoD for REGN-COV2 anti-viral antibody cocktailContinue

Tonix Pharma announced plans for Massachusetts R&D facility to accelerate clinical development of vaccines and protein-based therapeutics
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Tonix Pharma announced plans for Massachusetts R&D facility to accelerate clinical development of vaccines and protein-based therapeutics

On Jul. 7, 2020, Tonix Pharmaceuticals announced its intent to purchase an approximately 40,000 square foot facility in…

Read More Tonix Pharma announced plans for Massachusetts R&D facility to accelerate clinical development of vaccines and protein-based therapeuticsContinue

Anixa Biosciences and OntoChem announced completion of initial screening program and identification of additional Covid-19 compounds
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Anixa Biosciences and OntoChem announced completion of initial screening program and identification of additional Covid-19 compounds

On Jul. 6, 2020, Anixa Biosciences announced that it and partner OntoChem had completed the initial in silico…

Read More Anixa Biosciences and OntoChem announced completion of initial screening program and identification of additional Covid-19 compoundsContinue

WHO discontinued hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | WHO

WHO discontinued hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19

On Jul. 4, 2020, the World Health Organization (WHO) accepted the recommendation from the Solidarity Trial’s International Steering…

Read More WHO discontinued hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19Continue

CytoDyn announced exclusive agreement for distribution and supply of leronlimab for treatment of COVID-19 in U.S.
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

CytoDyn announced exclusive agreement for distribution and supply of leronlimab for treatment of COVID-19 in U.S.

On Jul. 3, 2020, CytoDyn announced it had signed an exclusive Distribution and Supply Agreement with American Regent…

Read More CytoDyn announced exclusive agreement for distribution and supply of leronlimab for treatment of COVID-19 in U.S.Continue

CDC announced action to prepare against ‘G4’ swine flu viruses in China with pandemic potential
Biotechnology | CDC | Diagnostics | Infectious Disease | Influenza | Vaccine

CDC announced action to prepare against ‘G4’ swine flu viruses in China with pandemic potential

On Jul. 2, 2020, the U.S. Centers for Disease Control and Prevention (CDC) announced a publication in the…

Read More CDC announced action to prepare against ‘G4’ swine flu viruses in China with pandemic potentialContinue

UConn-made COVID-19 custom mask solution to be manufactured
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

UConn-made COVID-19 custom mask solution to be manufactured

On Jul. 2, 2020, UConn announced a licensing deal with Connecticut Biotech, a startup company headquartered in South…

Read More UConn-made COVID-19 custom mask solution to be manufacturedContinue

Altimmune announces dosing of first patient in phase 1b clinical trial of NasoShield single dose intranasal anthrax vaccine candidate
Biotechnology | Infectious Disease | Vaccine

Altimmune announces dosing of first patient in phase 1b clinical trial of NasoShield single dose intranasal anthrax vaccine candidate

On Jun. 30, 2020, Altimmune announced dosing of the first patient in the Company’s Phase 1b clinical trial…

Read More Altimmune announces dosing of first patient in phase 1b clinical trial of NasoShield single dose intranasal anthrax vaccine candidateContinue

NIH study showed genomic variation causing common autoinflammatory disease may increase resilience to bubonic plague
Biotechnology | Diagnostics | Infectious Disease | Plague

NIH study showed genomic variation causing common autoinflammatory disease may increase resilience to bubonic plague

On Jun. 29, 2020, National Institutes of Health (NIH) researchers announced they had discovered that Mediterranean populations may…

Read More NIH study showed genomic variation causing common autoinflammatory disease may increase resilience to bubonic plagueContinue

Bharat Biotech COVID-19 vaccine – COVAXIN received DCGI approval for phase I & II Human clinical trials
COVID-19 | Infectious Disease | Vaccine

Bharat Biotech COVID-19 vaccine – COVAXIN received DCGI approval for phase I & II Human clinical trials

On Jun. 29, 2020, Bharat Biotech announced it had successfully developed COVAXIN, India’s 1st vaccine candidate for COVID-19,…

Read More Bharat Biotech COVID-19 vaccine – COVAXIN received DCGI approval for phase I & II Human clinical trialsContinue

MSFHR funded COVID-19 research to mitigate effects on BC’s vulnerable populations
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Non-Profit Research | Therapeutics | Vaccine

MSFHR funded COVID-19 research to mitigate effects on BC’s vulnerable populations

On Jun. 29, 2020, the Michael Smith Foundation for Health Research (MSFHR) COVID-19 Research Response Fund announced funding…

Read More MSFHR funded COVID-19 research to mitigate effects on BC’s vulnerable populationsContinue

SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 million
Biotechnology | Infectious Disease | Therapeutics

SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 million

On Jun. 25, 2020, SIGA Technologies announced the deliveries of oral TPOXX (tecovirimat) to the U.S. Department of…

Read More SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 millionContinue

Page navigation

Previous PagePrevious 1 … 42 43 44 45 46 … 68 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cardiovascular
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search